AI Biologics Design: Chai Discovery & Eli Lilly Partnership
Eli Lilly's partnership with Chai Discovery aims to revolutionize biologic drug design using AI, potentially achieving hit rates of 20% in antibody development.
- Publisher
- IntuitionLabs
- Published
- Length
- 21 pages
- File
- 571 KB PDF
Download the full 21-page PDF
Free · 571 KB · Instant access after email
The collaboration between Chai Discovery and Eli Lilly marks a significant advancement in AI-driven biologics design. Key findings include:
- Chai Discovery's AI platform, Chai-2, claims 20% hit rates for antibody design, far exceeding traditional methods.
- The partnership is valued at $1.3 billion following a $130 million Series B funding round.
- Eli Lilly aims to integrate AI across its R&D, with multiple initiatives underway.
- Analysts predict first-in-class biologics could enter trials by 2027.
- Challenges remain regarding real-world validation and integration of AI systems.
Ready to read the full report?
Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.
More whitepapers like this
Strategies to Enhance Recruitment of Female Participants to Cardiovascular Research
This consensus document outlines strategies to increase female representation in cardiovascular clinical trials, addressing significant under-representation of women.
British Society of Gastroenterology Guidelines on Inflammatory Bowel Disease in Adults: 2025
The updated BSG guidelines emphasize the necessity of ileocolonoscopy for IBD diagnosis and advocate for immunomodulators in all patients.
🔒 Agentic AI for Pharma Launches: Access & Engagement
Agentic AI can enhance pharma launches by improving market access and HCP engagement, with potential efficiency gains of up to 80%.